DRG Epidemiology's coverage of OPE comprises epidemiological estimates of key patient populations across 14 mature and emerging pharmaceutical markets worldwide. We report the prevalence of OPE for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.
DRG Epidemiology's OPE forecast will answer the following questions:
Of all people with OPE, how many in each country across the major mature pharmaceutical markets have been formally diagnosed?
Of all people diagnosed with OPE, how many in each country across the major mature pharmaceutical markets are drug-treated?
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of OPE over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
DRG Epidemiology provides at least ten years of forecast data for the following OPE patient populations:
Total Prevalence of Osteopenia per 1,000 Among People Aged 40+ in 2021 and 2041
Relative Sizes of the Contributing Factors to the Trend in Osteopenia Over the Next 20 Years
Analysis of the Prevalent Cases of Osteopenia in 2017 by Diagnosed and Drug-Treated Status
Epidemiology Data
Methods
Total Prevalent Cases
Diagnosed and Drug-Treated Prevalent Cases
Reference Materials
Literature Review
Studies Included in the Analysis of Osteopenia
Studies Excluded from the Analysis of Osteopenia
Risk/Protective Factors
Risk/Protective Factors for Osteopenia
Bibliography
Abbreviations
Glossary
Surup Dey
Surup Dey, M.L.T., M.P.H., is an epidemiologist at Clarivate. Previously, he worked in the field of medical diagnostic microbiology and was involved in the diagnosis of rare hematological disorders. Mr. Dey has a background in medical laboratory science from Christian Medical College in Vellore and a postgraduate degree in public health specializing in epidemiology from Manipal University.
Swarali Tadwalkar
Swarali Tadwalkar, M.P.H., is a principal epidemiologist at Clarivate. Previously, she was involved in primary and secondary healthcare research, including projects in digital health, health policy and management, and health economics and outcomes research (HEOR). Ms. Tadwalkar also coordinated various nongovernmental public health projects focusing on access to treatment for hepatitis and human papilloma virus. She received her M.P.H. from the University of South Florida in Tampa.
